The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 2×
“…which has been associated with normalization of the sensory motor gating and eye tracking abnormalities in schizophrenia (Adler et al. 1993; Freedman et al. 1997; Olincy et al. 1998) and desensitization of the a7 nicotinic receptor (Benwell et al. 1995; Fenster et al. 1999; Reitsletter et…”
BackgroundPrevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678
Frazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01187.1998 · Cited by 374
Benwell, M. E. M., Balfour, D. J. K., & Birrell, C. E. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13248.x · Cited by 169
Aggleton, J. P., Keith, A. B., Rawlins, J. N. P., Hunt, P. R., & Sahgal, A. (1992) · Behavioural Brain Research · doi:10.1016/s0166-4328(05)80325-0 · Cited by 161
Reitstetter, R., Lukas, R. J., & Gruener, R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38184-4 · Cited by 87
Cited by
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 560
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Muscarinic acetylcholine receptors as CNS drug targets
Langmead, C. J., Watson, J., & Reavill, C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.009 · Cited by 419
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Metadata
- Authors
- Friedman, J.
- Venue
- Psychopharmacology
- Published
- 2004-02-19
- Volume
- 174
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2073988872
- Cited by
- 184
- References
- 9
- FWCI
- 11.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. https://app.cochat.ai/papers/10.1007/s00213-004-1794-x
- The paper
- Friedman, J. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology. https://doi.org/10.1007/s00213-004-1794-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.